Edition:
United Kingdom

Geron Corp (GERN.OQ)

GERN.OQ on NASDAQ Stock Exchange Global Select Market

2.23USD
23 Feb 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$2.23
Open
$2.25
Day's High
$2.25
Day's Low
$2.13
Volume
258,859
Avg. Vol
380,553
52-wk High
$3.14
52-wk Low
$1.75

Latest Key Developments (Source: Significant Developments)

Geron-Latest Time For Janssen Continuation Decision To Continue Development Of Imetelstat In Any Indication Expected By Q4 2018/Q1 2019
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Geron Corp ::GERON -LATEST TIME FOR JANSSEN CONTINUATION DECISION TO CONTINUE DEVELOPMENT OF IMETELSTAT IN ANY INDICATION EXPECTED BY Q4 2018/Q1 2019 - SEC FILING‍​.  Full Article

Geron says first patient dosed in expanded part 1 of imerge clinical trial in myelodysplastic syndromes
Monday, 20 Nov 2017 

Nov 20 (Reuters) - Geron Corp ::Geron announces first patient dosed in expanded part 1 of imerge clinical trial in myelodysplastic syndromes.  Full Article

Geron Corp Q3 loss per share $0.04
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Geron Corp ::Geron Corporation reports third quarter 2017 financial results.Q3 loss per share $0.04.Q3 revenue $163,000.Q3 earnings per share view $-0.05 -- Thomson Reuters I/B/E/S.Q3 revenue view $264,000 -- Thomson Reuters I/B/E/S.  Full Article

Geron announces fast track designation grant for imetelstat
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Geron Corp :Geron announces fast track designation granted to imetelstat for lower risk myelodysplastic syndromes.Geron Corp - FDA grants fast track designation for potential treatment of adult patients with transfusion-dependent anemia​.Geron- J‍anssen sponsored application for fast track designation using preliminary data from clinical trial being conducted by Janssen in lower risk MDS​.  Full Article

Geron Corp Q2 loss per share $0.05
Wednesday, 3 Aug 2016 

Geron Corp : Q2 loss per share $0.05 . Q2 revenue $211,000 . Geron corporation reports second quarter 2016 financial results and recent events . Q2 earnings per share view $-0.07 -- Thomson Reuters I/B/E/S .Q2 revenue view $302,000 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Geron-Latest Time For Janssen Continuation Decision To Continue Development Of Imetelstat In Any Indication Expected By Q4 2018/Q1 2019

* GERON -LATEST TIME FOR JANSSEN CONTINUATION DECISION TO CONTINUE DEVELOPMENT OF IMETELSTAT IN ANY INDICATION EXPECTED BY Q4 2018/Q1 2019 - SEC FILING‍​ Source text (http://bit.ly/2COKF0K) Further company coverage: